Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

about

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

Item

http://www.wikidata.org/entity/Q55428234

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Neoadjuvant chemotherapy in br ...... tive role of PIK3CA mutations.

@en

Neoadjuvant chemotherapy in br ...... tive role of PIK3CA mutations.

@nl

type

Item

label

Neoadjuvant chemotherapy in br ...... tive role of PIK3CA mutations.

@en

Neoadjuvant chemotherapy in br ...... tive role of PIK3CA mutations.

@nl

prefLabel

Neoadjuvant chemotherapy in br ...... tive role of PIK3CA mutations.

@en

Neoadjuvant chemotherapy in br ...... tive role of PIK3CA mutations.

@nl

P1476

Neoadjuvant chemotherapy in br ...... tive role of PIK3CA mutations.

@en

P2093

Alberto Bafile

http://www.w3.org/2001/XMLSchema#string

Alessandra Tessitore

http://www.w3.org/2001/XMLSchema#string

Antonella Dal Mas

http://www.w3.org/2001/XMLSchema#string

Antonietta Ciccozzi

http://www.w3.org/2001/XMLSchema#string

Azzurra Irelli

http://www.w3.org/2001/XMLSchema#string

Corrado Ficorella

http://www.w3.org/2001/XMLSchema#string

Edoardo Alesse

http://www.w3.org/2001/XMLSchema#string

Enrico Ricevuto

http://www.w3.org/2001/XMLSchema#string

Gino Coletti

http://www.w3.org/2001/XMLSchema#string

Giuseppe Calvisi

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.

P304

27380-27396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25270

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29937992

http://www.w3.org/2001/XMLSchema#string

P932

6007957

http://www.w3.org/2001/XMLSchema#string